AIGEN Sciences Inc. is at the forefront of revolutionizing drug discovery through its advanced AI-driven platform, which aims to enhance the efficiency and success rates of drug development processes. The company focuses on the direct discovery of high-potency drugs that effectively target desired cellular activities while minimizing off-target effects and toxicity. By leveraging state-of-the-art AI technologies, AIGEN Sciences seeks to transform traditional, high-cost drug discovery practices into rapid and efficient methodologies, ultimately leading to improved outcomes in clinical phases.

The company has established numerous research collaborations and partnerships with various organizations, including YUHAN and NOVELTY NOBILITY Inc., to explore mechanisms of anti-cancer drugs and develop novel antibody-drug conjugates (ADCs). AIGEN Sciences has also secured significant funding to accelerate its research and development pipeline, with plans to advance multiple drug candidates by 2023. The foundation of AIGEN Sciences is rooted in the expertise of the Korea University DMIS Lab, from which it spun off, and it has consistently demonstrated its capabilities by winning prestigious awards in international AI competitions related to biomedical research and drug discovery.

South Korea

We aim to advance current state-of-the-art AI drug discovery technologies and transform high-cost, low-efficiency drug discovery practices into rapid, efficient discovery, ultimately leading to high success rates in the clinical phase.

Our award-winning AI drug discovery platform enables the direct discovery of high potency drugs that induce desired cellular-level activity with minimal off-target effects and toxicity.

AIGEN Sciences will revolutionize AI-based drug discovery.

AIGEN Sciences Inc.

Company Details